Nanobiotix and Johnson & Johnson Advance Nothereapeutics in Collaboration
What happened
The collaboration between Johnson & Johnson and Nanobiotix regarding nanotherapeutics began on September 1, 2026. Nanobiotix reported that its successful follow-on offering of approximately €86 million extended its cash runway into 2029, with the company holding €110.9 million in cash and cash equivalents as of June 30, 2026. The companies also reported acceptable safety profiles and promising initial efficacy responses in the Johnson & Johnson-led Phase 2 CONVERGE study evaluating JNJ-1900 (NBTXR3).
From manilatimes.net
Why it matters
The partnership focuses on the joint development of nanotherapeutics, with JNJ-1900 (NBTXR3) undergoing trials for various indications. The successful completion of clinical phases and the financial stability of Nanobiotix support the belief that this approach has potential to revolutionize treatment possibilities.
From manilatimes.net
Who's involved
- Johnson & JohnsonU.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer partnered on nanotherapeutics.
- NanobiotixFrench healthcare company partnered with Johnson & Johnson on the joint development of nanotherapeutics.
Keep exploring
The entities involved
-
Johnson & Johnson
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer
-
Nanobiotix
French healthcare company
Nothing else this week.